Materiały źródłowe

• #1 Chronic Granulomatous Disease: Epidemiology, Pathophysiology, and Genetic Basis of Disease

  https://pmc.ncbi.nlm.nih.gov/articles/PMC5946813/

  Chronic Granulomatous Disease is one of the classic primary immunodeficiencies of childhood. […] the estimated incidence of CGD is 1 in ~200000 live births. […] Given the annual US birth cohort of nearly 4 million infants, approximately 20 children each year are born with CGD. […] Estimates of the incidence of CGD in Europe and Asia are similar, although some populations are affected more often, including the Arab population of Israel, in which the incidence is estimated to be 1.5 per 100000 live births. […] Survival rates have increased steadily over time. In the 1960s, the mortality rate was 60% by 7 years of age, whereas data published in the last 10 years suggest that at least 50% of these patients remain alive 25 years after diagnosis.

• #2 Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis – UpToDate

  https://www.uptodate.com/contents/chronic-granulomatous-disease-pathogenesis-clinical-manifestations-and-diagnosis/print

  Chronic granulomatous disease (CGD) is a genetically heterogeneous condition characterized by recurrent, life-threatening bacterial and fungal infections and granuloma formation. […] The frequency of CGD in the United States is approximately 1:200,000 live births. […] The disease primarily affects males since over 50 percent of the pathogenic variants are X linked. […] CGD may present at any time from infancy to late adulthood, but the majority of patients are diagnosed as toddlers and children before the age of five years. […] A growing number of patients are diagnosed in later childhood or adulthood due in part to recognition of milder cases of autosomal recessive CGD, as well as delayed diagnosis in some patients. […] X-linked CGD tends to have an earlier onset and be more severe than the most common autosomal recessive form, p47phox deficiency.

• #2 Chronic Granulomatous Disease: Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/1116022-overview

  Chronic granulomatous disease (CGD) is a rare (1:250,000 births) disease caused by mutations in any one of the five components of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in phagocytes. […] The exact incidence of chronic granulomatous disease (CGD) is unknown. CGD affects approximately 1 infant per 200,000-250,000 live births. […] The prevalence of CGD varies among the populations investigated, with studies reporting variations from 1 case per 1 million individuals to 1 case per 160,000 individuals. […] Chronic granulomatous disease affects persons of all races. […] Approximately 80% of patients with CGD are male, because the main cause of the disease is a mutation in an X-chromosome-linked gene. However, defects in autosomal genes may also underlie the disease and cause CGD in both males and females. […] Symptom onset typically occurs at a young age, although the diagnosis has been at an older age in some patients. Typically, patients with CGD have recurrent pyogenic infections that start in the first year of life. Occasionally, the onset may be delayed until the patient is aged 10-20 years.

• #3 Chronic granulomatous disease – Wikipedia

  https://en.wikipedia.org/wiki/Chronic_granulomatous_disease

  CGD affects about 1 in 200,000 people in the United States, with about 20 new cases diagnosed each year. […] Chronic granulomatous disease affects all people of all races; however, there is limited information on prevalence outside of the United States. One survey in Sweden reported an incidence of 1 in 220,000 people, while a larger review of studies in Europe suggested a lower rate: 1 in 250,000 people.

• #4 Orphanet: Chronic granulomatous disease

  https://www.orpha.net/en/disease/detail/379

  Chronic granulomatous disease (CGD) average worldwide birth prevalence is estimated between 1/100,000 and 1/217,000. […] A mutation in the CYBB gene (Xp21.1) is seen in 65% of cases in North America and Western Europe. […] Genetic counseling is possible in families when a disease-causing gene has been identified.

• #5

  https://link.springer.com/article/10.1007/s12325-017-0636-2

  Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by defects in any of the five subunits of the NADPH oxidase complex responsible for the respiratory burst in phagocytic leukocytes. […] The incidence of CGD in the United States and Europe is around 1 in 200,000 to 1 in 250,000 live births. […] However, the incidence varies significantly worldwide, from 1:1 million in Italy to 1:70,000 in the Israeli Arab population, and, in countries with high rates of consanguinity, the rate of autosomal recessive CGD exceeds that of X-linked CGD. […] CGD may present at any age from infancy to late adulthood; however, the vast majority of patients are diagnosed at less than 5 years of age. […] In general, patients with X-linked CGD have a more severe disease course with earlier age at presentation and earlier age of death.

• #5

  https://link.springer.com/article/10.1007/s12325-017-0636-2

  The survival of patients with CGD is strongly associated with residual superoxide production independent of the specific gene affected. […] Life expectancy of CGD patients has increased more than three-fold over the last few decades due to increased recognition of the disease, the advent of azole antifungals, and improved management of infectious and inflammatory complications. […] Nevertheless, the incidence of triazole-resistant Aspergillus is increasing, and the management of inflammatory complications remains difficult. […] Survival following HCT has increased from approximately 85% before 2000 to greater than 90% in recent reports, and outcomes have been encouraging regardless of the donor source. […] Children who undergo HCT are also healthier with better QoL than those managed conservatively.

• #5

  https://link.springer.com/article/10.1007/s12325-017-0636-2

  As such, HCT should be considered for all patients with CGD regardless of sex, genetic mutation, and clinical manifestations. […] MAC appears to reduce the risk of graft failure and increase the likelihood of long-term myeloid engraftment. […] It is preferable to perform HCT as early as possible, but definitive cure can also be considered for adolescent and young adult patients, including those with a history of severe infection and autoinflammation. […] Ultimately, as HCT becomes more widely available and better tolerated, we expect overall life expectancy for patients with CGD to increase substantially over the next several years. […] Furthermore, with the new SIN-lentiviral vectors and optimization of conditioning regimens, gene therapy may become a viable alternative to allogeneic HCT for those without an HLA-matched donor.

• #6 Chronic Granulomatous Disease | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/19527

  CGD occurs in 1 in every 200,000 live births in the United States. Due to the X-chromosome-linked gene mutation, approximately 80% of patients with CGD are males. The incidence rates are nearly identical across ethnic and racial groups, and approximately one-third of the X-linked mutations occur in de-novo. In cultures where consanguineous marriage is common, the autosomal recessive subtype of the disease is more common than the X-linked recessive forms, and the overall incidence rates are higher. Children with the X-linked variant of CGD tend to have an earlier onset and suffer a more severe disorder than the autosomal recessive form.

• #7 Chronic Granulomatous Disease | Concise Medical Knowledge

  https://www.lecturio.com/concepts/chronic-granulomatous-disease/

  Equally identified in all ethnicities and races. Estimated incidence approximately 1 case per 200,000 live births per year. Predominant in males (65%-70% of cases are from an X-linked mutation). Most patients now survive until 30-40 years of age. Mortality elevated after age 10 years. The X-linked form of the disease is associated with the highest mortality and morbidity. […] The introduction of antimicrobial prophylaxis and the use of azole antifungals has increased the overall life expectancy of these patients.

• #8 Pediatric Chronic Granulomatous Disease: Practice Essentials, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/956936-overview

  No racial predilection is known. […] About two thirds of cases are inherited as X-linked defects, and the remaining cases are inherited in autosomal recessive fashion. Of 368 patients from 318 kindreds reported to the CGD registry, 316 (86%) were male. […] Although the vast majority of affected individuals present with infections in early childhood, several reports describe affected patients who became symptomatic later than this. CGD is probably undiagnosed in some patients because they have a clinically mild phenotype.

• #8 Pediatric Chronic Granulomatous Disease: Practice Essentials, Pathophysiology, Epidemiology

  https://emedicine.medscape.com/article/956936-overview

  The exact incidence of CGD is unknown. Analysis of data submitted to a national registry suggests that the incidence of CGD in the United States is about 1 case per 200,000-250,000 population (as many as 20 patients with CGD are born each year), with no apparent racial or ethnic predilection. […] Surveys from the Netherlands and other parts of the world suggest a frequency of about 1 case per 220,000-500,000 population. […] A detailed study of the natural history of CGD is unavailable. The aforementioned US registry data suggest that morbidity and mortality rates are highest in patients with the X-linked form of the disease. A substantial number of patients in the registry died during the second and third decades of life, though some survived beyond the fourth decade. Approximately 80% of patients were alive at 5 years after they were entered in the registry. Even in the modern age of care for this disease, sporadic data suggest a potential excess in mortality in individuals aged 10-30 years.

• #9 Clinical and demographic pattern of chronic granulomatous disease (CGD) from a multicenter perspective: Malaysia’s experience over 26 years | Allergy, Asthma & Clinical Immunology | Full Text

  https://aacijournal.biomedcentral.com/articles/10.1186/s13223-021-00551-4

  The mean age of diagnosis was 3.7 years. […] The most common clinical presentation of the patients was abscesses, (N=16, 80%; skin=10, spleen=3, liver=3, bone=1, brain=1, muscle=1) followed by pneumonia (N=10, 50%) with one complicating as bronchiectasis. […] The microbiological profile of the patients was predominantly of the catalase-positive bacteria as shown in Table 3. […] It is noteworthy that a study done in a province in Saudi Arabia reported that all of their patients were autosomal recessive inheritance with a point prevalence of 6.4 per 100,000, the highest being reported up to 2009 in the literature. […] The mortality rate of CGD patients with C. violaceum infection is very much lower (7%) in the Southeast US as compared to Malaysia at 80%. […] We have shown that CGD is prevalent in Malaysia and that similar prevalence could occur in South East Asia region.

• #9 Clinical and demographic pattern of chronic granulomatous disease (CGD) from a multicenter perspective: Malaysia’s experience over 26 years | Allergy, Asthma & Clinical Immunology | Full Text

  https://aacijournal.biomedcentral.com/articles/10.1186/s13223-021-00551-4

  A retrospective review of clinical manifestations and demographic pattern of patients diagnosed as chronic granulomatous disease (CGD) from 7 hospitals in Malaysia. […] The prevalence of the disease is not well described in many developing countries. A study in the United States (US) estimated the incidence of CGD is between 1 in 200,000 to 1 in 250,000 live births. […] Chronic granulomatous disease cases in Malaysia were first reported in 1994 diagnosed in two unrelated boys based on nitroblue tetrazolium dye test (NBT) and chemiluminescence assay (CA); and this would have been the first report from South East Asia (SE Asia). […] This report would be the first patient series in SE Asia, revealing some inherent differences in the clinical and demographic patterns from the Europe, America and Asia.

• #10 Chronic Granulomatous Disease (CGD): Commonly Associated Pathogens, Diagnosis and Treatment

  https://www.mdpi.com/2076-2607/11/9/2233

  Chronic granulomatous disease (CGD) is a rare inherited primary immunodeficiency, that was first reported as a “Fatal granulomatous disease of childhood” owing to the early death of children with this condition, and has been described by some other authors. Pediatric CGD is relatively rare; this genetic condition, which has variable ethnic associations, occurs in 1 out of every 200,000–250,000 births in the United States and is often diagnosed in the first three years of life. According to data from European nations, approximately 65% of patients with CGD have a molecular defect in CYBB (most are hemizygous males). Autosomal recessive CGD accounts for approximately 30% of all CGD cases. Molecular defects in any of these five genes (CYBB for gp91phox (located on the X chromosome), CYBA for p22phox, NCF1 for p47phox, NCF2 for p67phox, and NCF4 for p40phox) can occur in 90% of patients with CGD. They harbour mutations in the CYBB (gp91phox) or NCF1 (p47phox) genes. Symptoms may be delayed in some patients with residual activity. In most countries, the offspring of CGD consanguineous marriages or unions is at increased risk of CGD due to expressing autosomal recessive gene mutations inherited from common CGD ancestors. Therefore, consanguineous unions increase the incidence of this condition, which sometimes is not detected quickly enough, and death from infectious diseases may occur. A large cohort study suggested that North African/Arab and Turkish immigrants in Europe have a high prevalence of autosomal recessive CGD, reflecting the increased prevalence of consanguineous marriage in these populations. The study proves that pulmonary sites occur more in number, which is well illustrated by this European study. Approximately 1.49 per every 10,000 live births in the Israeli Arab population and 1.05 in the Israeli Jewish population have CGD, primarily associated with an autosomal recessive inheritance, displaying increased morbidity. Late presentation of CGD has been reported. CGD derives its name from the characteristic formation of multiple granulomas in various body tissues. Granulomas often occur anywhere in the GI tract, from the mouth to the anus, with the colon and oesophagus being the most and least common sites, respectively.

• #11 Diagnosis of Chronic Granulomatous Disease: Strengths and Challenges in the Genomic Era

  https://www.mdpi.com/2077-0383/13/15/4435

  Chronic granulomatous disease (CGD) is felt overall to be a rare disease, with varied reported estimates of prevalence, which differ geographically and by population rate of consanguinity. In Western Europe and the US, prevalence is reported as 1 in 200,000–250,000. The clinical spectrum of CGD varies in terms of disease manifestations, severity and age at presentation, which presents a challenge to recognition and diagnosis. Severe cases (predominantly X-linked recessive in inheritance), tend to present early at 9–14 months of age, and are diagnosed early at 2.1–4.9 years. Milder cases (predominantly autosomal recessive) tend to present later at 2.5–3.4 years, and are also diagnosed later at 5.8–8.8 years. Diagnoses in early infancy, adolescence and adulthood are unusual, but occur increasingly due to increased awareness and uptake of testing.

• #11 Diagnosis of Chronic Granulomatous Disease: Strengths and Challenges in the Genomic Era

  https://www.mdpi.com/2077-0383/13/15/4435

  The European Society for Immunodeficiencies (ESID) registry provides working definitions for definite and probable cases of CGD, which reflect the clinical features described above, and require laboratory testing of both the respiratory burst pathway and genetics. […] Routine newborn population screening for CGD is not commonplace, despite the potential benefits of early diagnosis. This is due at least in part to the infeasibility of a CGD-relevant screening assay, which can be run in parallel with other tests, although potential assays have been proposed using mass spectrometry for protein detection in newborn dried blood spot samples. Screening of asymptomatic individuals is thus usually restricted to family members of known CGD probands. However, there is growing interest in the use of genomic tests for newborn screening, and it is timely that five CGD-related genes are included in those to be tested in the Generation Study of newborn genomic screening currently being piloted in sites across the UK. This furthermore emphasises the need for reliable and accurate confirmatory diagnostic testing for screen-positive individuals identified prior to onset of any infective or other complications.

• #12 Chronic Granulomatous Disease | 5-Minute Pediatric Consult

  https://peds.unboundmedicine.com/pedscentral/view/5-Minute-Pediatric-Consult/617724/all/Chronic_Granulomatous_Disease?q=Hepatomegaly

  Chronic granulomatous disease (CGD) is a rare, primary immunodeficiency caused by a genetic defect that results in an inability of phagocytes to generate superoxide, which is important in microbial killing. Affected individuals are susceptible to recurrent, life-threatening bacterial and fungal infections. […] 1:200,000 to 1:250,000 live births in the United States and Europe. Rates in other countries vary depending on ethnic practices and degree of intermarriage.

• #13

  https://link.springer.com/article/10.1007/s10875-023-01541-4

  Chronic granulomatous disease (CGD) is an inherited primary immunodeficiency disorder of phagocytes, characterized by recurrent fungal and bacterial infections. Our aim is to describe the different clinical presentations, non-infectious auto-inflammatory features, types and sites of infections, and to estimate the mortality among our large cohort. […] This is a retrospective study conducted at the Pediatric Department of Cairo University Childrens Hospital in Egypt, including cases with a confirmed CGD diagnosis. […] One hundred seventy-three confirmed CGD patients were included. AR-CGD was diagnosed in 132 patients (76.3%) including 83 patients (48%) with p47phox defect, 44 patients (25.4%) with p22phox defect, and 5 patients (2.9%) with p67phox defect. XL-CGD was diagnosed in 25 patients (14.4%). The most common recorded clinical manifestations were deep-seated abscesses and pneumonia.

• #13

  https://link.springer.com/article/10.1007/s10875-023-01541-4

  Regarding the outcome, 36 patients (20.8%) were lost from follow-up. Among patients with known outcome, 94/137 patients (68.6%) are living, while 43/137 patients (31.4%) died. […] AR-CGD is predominant in Egypt; CGD must always be ruled out in any patient presenting with typical or atypical mycobacterial or BCG-disease. […] The geographical distribution of CGD patients in Egypt was the following: Upper Egypt; 4 patients with gp91phox defect, 25 patients with p47phox defect, 11 patients with p22phox defect, and 2 patients with p67phox defect. Cairo Metropolitan area; 6 patients with gp91phox defect, 25 patients with p47phox defect, 7 patients with p22phox defect, and 1 patient with p67phox defect. […] Positive consanguinity was reported in 141 (81.5%) patients with 91.7% consanguinity among AR-CGD. Fifty-seven (32.9%) patients had a history of previous sibling death and 28% with siblings affection.

• #13

  https://link.springer.com/article/10.1007/s10875-023-01541-4

  The median age at diagnosis was 48 months (range 1186 months), while the median age at presentation was 7 months (range 0.2180 months). […] The most common isolated organism from pulmonary infections was Aspergillus sp., followed by gram-negative bacteria then Mycobacterial sp., like in many reports. […] Pneumonia was the most common cause of death in 32 patients (74.4%), and the causative organisms were the following: 16/32 bacteria, 10/32 invasive aspergillosis, 4/32 Mycobacterial species, 1 Mucormycosis, and 1 Candida sp. resistant to Azole, followed by septicemia in 7 patients (16.2%). […] The mortality rate in our cohort was 31.4% which is lower than Indian and Mexican reports and higher than those reported in Europe and Israel.

• #14 Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France. – Research – Institut Pasteur

  https://research.pasteur.fr/en/publication/epidemiology-and-outcome-of-invasive-fungal-diseases-in-patients-with-chronic-granulomatous-disease-a-multicenter-study-in-france/

  Chronic granulomatous disease (CGD) is a rare inherited phagocytic disorder resulting in an increased susceptibility to infections including invasive fungal diseases (IFDs) and inflammatory complications. This study is aimed at assessing the incidence, prevalence, and outcome of IFDs among CGD patients followed in France. CGD patients were identified through the French national registry for primary immunodeficiencies (PID) held by the French national reference Centre of PID (Centre de Rfrence Dficits Immunitaires Hrditaires), which comprises a total of 3083 patients including 155 with CGD followed between 1976 and 2008. Of CGD patients, 42.6% (66/155) developed at least 1 episode of IFD. Overall incidence of IFD was 0.040/patient-years (1862 patient-years of total follow-up). IFD incidence was found to be significant while receiving itraconazole prophylaxis compared with no prophylaxis (0.027 vs. 0.053 IFD/patient-years; P 0.01). IFDs are a frequent and life-threatening complication in CGD patients. Itraconazole significantly reduces its incidence and should be recommended in absence of better alternatives.

• #15 Chronic Granulomatous Disease: The European Experience | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0005234

  Chronic granulomatous disease (CGD) is an uncommon inherited immunodeficiency, occurring in about one in 250,000 individuals. […] To further improve knowledge of the course of CGD, clinical data from European patients were collected. We now report our findings in 429 European patients, the largest cohort of CGD patients to date. […] Conspicuously absent in this database were patients from the United Kingdom, Ireland and Italy. In these countries national registries of the clinical data from CGD patients were being constructed independently, the data of which have recently been published separately. […] A weakness of this cohort is the absence of patients from two large European countries, the UK and Italy. […] It is still not possible to determine the true incidence and prevalence of CGD. From this cohort one would discern that in the Netherlands the prevalence of CGD is high (62 cases on a population of 16 million), and even higher in Denmark (22 cases on a population of 5.5 million). Most likely these numbers are due to a high awareness of the disease.

• #15 Chronic Granulomatous Disease: The European Experience | PLOS One

  https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0005234

  The data presented in this paper have confirmed earlier reports and show a clear statistically significant difference in life span between the two main types of CGD, although it is important to keep in mind that there have been individual AR-CGD patients with early and extremely severe expression of the disease. […] The isolated micro-organisms roughly correspond to the pathogens known to be important in CGD. However, many cultures remained negative, perhaps owing to previous long-term antibiotic/antifungal prophylactic therapy. […] Our data also confirm an increased susceptibility to BCG-itis in CGD patients, as has been recently described. This newly described feature warrants further investigation. […] Further investigations should be performed in a prospective manner, including data from more European countries.

• #16 Top Published Expert Doctors for Chronic Granulomatous Disease

  https://findexpertmd.com/d/Chronic_Granulomatous_Disease

  582 top medical experts on Chronic Granulomatous Disease across 45 countries and 28 U.S. states, including 481 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants. […] Clinical Trials ClinicalTrials.gov : at least 64 including 3 Active, 22 Completed, 17 Recruiting.

• #17 Methylotroph Infections and Chronic Granulomatous Disease – Volume 22, Number 3—March 2016 – Emerging Infectious Diseases journal – CDC

  https://wwwnc.cdc.gov/eid/article/22/3/15-1265_article

  Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by a defect in production of phagocyte-derived reactive oxygen species, which leads to recurrent infections with a characteristic group of pathogens not previously known to include methylotrophs. […] Methylotrophs are emerging as disease-causing organisms in patients with CGD. […] Geographic origin of the methylotroph strain may affect clinical management and prognosis. […] CGD infections are often caused by a characteristic group of pathogens, including Staphylococcus aureus, Serratia marcescens, Burkholdheria cepacia complex, Nocardia spp., and Aspergillus spp. […] We have identified a total of 12 infections caused by 3 methylotroph bacteria in patients with CGD: 2 A. methanolica, 1 M. lusitanum, and 9 G. bethesdensis infections.

• #18 Chronic granulomatous disease mimicking early-onset Crohn’s disease with cutaneous manifestations | BMC Pediatrics | Full Text

  https://bmcpediatr.biomedcentral.com/articles/10.1186/1471-2431-14-156

  Chronic granulomatous disease is a rare inherited disorder of the innate immune system. In patients with a clinical history of recurrent or persistent infections, especially infections caused by uncommon species, chronic granulomatous disease should be considered. […] In patients with a history of recurrent or persistent infections, particularly infections caused by uncommon species such as Aspergillus, Staphylococcus aureus, Serratia marcescens, Nocardia, and Burkholderia cepacia, CGD should be considered. […] A study by van den Berg et al. found that 48% of CGD patients had experienced at least one episode of gastrointestinal manifestation. […] CGD is a rare but important differential diagnosis of chronic inflammatory bowel disease in childhood. […] One interesting aspect of this case is the presence of a positive serological marker (ASCA).

• #18 Chronic granulomatous disease mimicking early-onset Crohn’s disease with cutaneous manifestations | BMC Pediatrics | Full Text

  https://bmcpediatr.biomedcentral.com/articles/10.1186/1471-2431-14-156

  Treatment for CGD, as for other immune deficiencies, is focused primarily on prevention with prophylactic antibiotic and antifungal therapy and therapy for potentially life-threatening infections. […] Protocols of continued intensive surveillance and monitoring compliance with anti-infective regimens can significantly improve the quality of life and long-term survival in patients with CGD. […] Clinicians and pathologists need to be aware that CGD is a differential diagnosis of CD, especially, but not exclusively, when occurring in early life.

• #19 Frontiers | Chronic Granulomatous Disease First Diagnosed in Adulthood Presenting With Spinal Cord Infection

  https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.01258/full

  The diagnosis of CGD in an early stage offers the possibility of long-term, low-dose antibiotics and antifungal prophylactic treatment, as well as interferon γ treatment, which is considered to possess a protective effect against infections. […] Chronic granulomatous disease is a life-threatening genetic immunodeficiency, which has to be diagnosed as early as possible to maintain prophylactic options including long-term antibiotic therapy.

• #20 Chronic Granulomatous Disease | Children’s Hospital of Philadelphia

  https://www.chop.edu/conditions-diseases/chronic-granulomatous-disease

  CGD is a rare condition, affecting about 8 people per million. […] At CHOP, we have followed more than 60 patients with CGD, and have treated nearly 30 with cellular therapy in the past 10 years. […] Diagnosis of CGD may be suspected based on signs and symptoms of the disorder, or family history. In most cases, symptoms of CGD appear by age 3. The vast majority of children with CGD are diagnosed by age 5. […] Regular blood tests are vitally important for children with chronic granulomatous disease because they often identify problems before symptoms arise and CGD can be treated early. […] CHOP’s PIICT follows CGD patients into adulthood, has a close collaboration with the Allergy and Immunology Program at the Hospital of the University of Pennsylvania, and supports patients as they transfer to adult care.

Zobacz więcej